Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome  Esther J. Kim, Daniel J. Lewis, Madeleine Duvic  Journal of Investigative Dermatology  Volume 137, Issue 9, Pages 1831-1833 (September 2017) DOI: 10.1016/j.jid.2017.06.013 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Pathogenetic and clinical features of PCLBCL-LT in different stages. PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg-type. Journal of Investigative Dermatology 2017 137, 1831-1833DOI: (10.1016/j.jid.2017.06.013) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Overview of NF-κB activation and the genetic aberrancies in PCLBCL-LT versus Sézary syndrome. Affected molecules in PCLBCL-LT are indicated in red, affected molecules in Sézary syndrome are indicated in blue, and therapeutic targets are indicated in green. CARD11, caspase recruitment domain family member 11; CD79A, cluster of differentiation 79A; CD79B, cluster of differentiation 79B; MYD88, myeloid differentiation primary response gene; PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg-type; TLR, toll-like receptor. Reprinted from Koens et al., 2014, with permission from Elsevier. Journal of Investigative Dermatology 2017 137, 1831-1833DOI: (10.1016/j.jid.2017.06.013) Copyright © 2017 The Authors Terms and Conditions